Drug
Pradigastat clinical trials
Also written LCQ908.
Includes 1 study of Pradigastat sodium.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 2009
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2012 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 2 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 7
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 0
Novartis Pharmaceuticals (10) · Anji Pharma (1)
Studies
Open first, then newest update. How each study uses pradigastat is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Proof of Concept Study of Pradigastat in Patients With Functional ConstipationCompletedPhase 2Anji PharmaNCT04620161Written as Pradigastat Tablets 20mg
- Pharmacokinetics of LCQ908 in Patients With Hepatic ImpairmentCompletedPhase 1Novartis PharmaceuticalsNCT01594957Written as LCQ908
- Pharmacokinetics of LCQ908 in Patients With Renal ImpairmentCompletedPhase 1Novartis PharmaceuticalsNCT01558323Written as LCQ908
- Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe HypertriglyceridemiaCompletedPhase 1/2Novartis PharmaceuticalsNCT01146522Written as LCQ908
- A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe HypertriglyceridemiaCompletedPhase 2Novartis PharmaceuticalsNCT01594983Written as LCQ908
- Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.TerminatedPhase 3Novartis PharmaceuticalsNCT01589237Written as LCQ908
- Efficacy of LCQ908 on Cardiovascular RiskTerminatedPhase 2Novartis PharmaceuticalsNCT01474434Written as pradigastat (LCQ908)
- Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01811472Written as LCQ908
- A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia SyndromeCompletedPhase 3Novartis PharmaceuticalsNCT01514461Written as LCQ908
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 2Novartis PharmaceuticalsNCT00901979Written as LCQ908A
- A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C PatientsTerminatedPhase 2Novartis PharmaceuticalsNCT01387958Written as LCQ908
Codes
What other systems call pradigastat · ClinicalTrials.gg INT000159
- MeSH (NLM) C000594809pradigastatOne source NLM
- UNII (FDA) 2U23G6VNUZPRADIGASTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27088438pradigastatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166592PradigastatOne source FDA
- DrugBank DB12866One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000594809 | pradigastat | One source NLM |
| UNII (FDA) | 2U23G6VNUZ | PRADIGASTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088438 | pradigastat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166592 | Pradigastat | One source FDA |
| DrugBank | DB12866 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.